Akari Therapeutics PLC (AKTX)
1.36
-0.11
(-7.48%)
USD |
NASDAQ |
May 03, 16:00
1.39
+0.03
(+2.21%)
Pre-Market: 20:00
Akari Therapeutics Enterprise Value: 6.931M for May 3, 2024
Enterprise Value Chart
Historical Enterprise Value Data
Date | Value |
---|---|
May 03, 2024 | 6.931M |
May 02, 2024 | 7.803M |
May 01, 2024 | 9.625M |
April 30, 2024 | 8.358M |
April 29, 2024 | 6.296M |
April 26, 2024 | 5.545M |
April 25, 2024 | 5.584M |
April 24, 2024 | 5.584M |
April 23, 2024 | 5.743M |
April 22, 2024 | 5.505M |
April 19, 2024 | 5.396M |
April 18, 2024 | 5.743M |
April 17, 2024 | 5.039M |
April 16, 2024 | 5.311M |
April 15, 2024 | 5.663M |
April 12, 2024 | 5.743M |
April 11, 2024 | 4.871M |
April 10, 2024 | 6.456M |
April 09, 2024 | 6.575M |
April 08, 2024 | 7.248M |
April 05, 2024 | 7.327M |
April 04, 2024 | 7.565M |
April 03, 2024 | 8.437M |
April 02, 2024 | 8.120M |
April 01, 2024 | 8.120M |
Date | Value |
---|---|
March 28, 2024 | 8.496M |
March 27, 2024 | 8.463M |
March 26, 2024 | 8.628M |
March 25, 2024 | 8.727M |
March 22, 2024 | 8.132M |
March 21, 2024 | 8.264M |
March 20, 2024 | 8.726M |
March 19, 2024 | 8.992M |
March 18, 2024 | 9.389M |
March 15, 2024 | 9.191M |
March 14, 2024 | 9.654M |
March 13, 2024 | 10.38M |
March 12, 2024 | 10.32M |
March 11, 2024 | 10.38M |
March 08, 2024 | 10.32M |
March 07, 2024 | 10.85M |
March 06, 2024 | 10.71M |
March 05, 2024 | 11.11M |
March 04, 2024 | 11.04M |
March 01, 2024 | 11.24M |
February 29, 2024 | 11.71M |
February 28, 2024 | 10.85M |
February 27, 2024 | 11.31M |
February 26, 2024 | 11.85M |
February 23, 2024 | 11.64M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
3.016M
Minimum
Mar 30 2023
135.22M
Maximum
Feb 19 2021
41.98M
Average
39.66M
Median
Jun 29 2022
Enterprise Value Benchmarks
DBV Technologies SA | -11.86M |
Cellectis SA | 44.93M |
Adaptimmune Therapeutics PLC | 146.78M |
Biodexa Pharmaceuticals Plc | -2.432M |
NuCana PLC | -13.49M |
Enterprise Value Related Metrics
Earnings Yield | -150.3% |